The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treat JIA Without Slowing Growth

Treat JIA Without Slowing Growth

January 4, 2011 • By By Sue Pondrom

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Juvenile idiopathic arthritis (JIA) patients treated with etanercept or etanercept plus methotrexate (MTX) experienced a statistically significant increase in mean height, weight, and body mass index (DMI) percentiles, according to researchers from the Cincinnati Children’s Hospital Medical Center. However, JIA patients treated with MTX alone did not display an increase in growth.

You Might Also Like
  • New Guidance for Rheumatologists who Treat JIA
  • Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
Also By This Author
  • ACR Meets with CMS Administrator

According to first author Edward Giannini, DrPh, MSc, “studies have shown that growth retardation is associated with systemic inflammation and is a potentially permanent complication of JIA.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study data indicate that etanercept may be safe to use in JIA patients long term, Dr. Giannini says. “Physicians administering etanercept to growing children, and the patients and families, can be comforted that this biologic does not interfere with normal growth and development,” he notes.

JIA is one of the most common rheumatic diseases in children, causing significant pain and functional disability. Prior studies have shown that JIA patients may experience impaired physical growth and development dependent upon the severity of chronic inflammation, longer duration of disease, and greater functional joint involvement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the new three-year, open-label, nonrandomized registry of 594 patients with polyarticular (90% of the subjects) or systemic (10% of the subjects) JIA, participants between the ages of two and 18 were treated with 0.4 mg/kg of etanercept twice weekly or 0.8mg/kg once weekly. The growth profiles for each patient were recorded at baseline and at Years One, Two, and Three, and were compared with the U.S. Centers for Disease Control and Prevention (CDC) standardized growth charts to obtain percentiles.

The mean height in the etanercept group significantly increased by 4.8 percentile points by Year Three. For patients in the etanercept plus MTX group, a significant increase in mean height in Years One, Two, and Three was also recorded, with 2.4, 3.3, and 5.6 percentiles, respectively. In the MTX-only group, the mean height percentiles showed nonsignificant decreases from baseline at Years One, Two, and Three.

Similar patterns were observed for other measures of growth, such as weight and BMI, with etanercept alone, or in combination with MTX. Mean changes in weight percentile from baseline were observed each year. In the group receiving etanercept only, increases at Years One, Two, and Three were 7.4, 10.0, and 13.0, respectively. In the etanercept plus MTX group, the respective increases were 2.9, 6.9, and 8.4. BMI percentiles increased from 9.6 to 13.8 percentile points in the etanercept-only group and from 2.1 to 5.2 percentile points in the etanercept-plus-MTX group. At the end of the three years, the mean weight percentile values were 60.1 for MTX, 56.5 for etanercept, and 55.0 for etanercept plus MTX. The mean BMI percentile values were 65.9 for MTX, 63.5 for etanercept, and 60.1 for etanercept plus MTX. No consistent effect of disease control on height was observed for any treatment groups during the study. Normal development, as assessed by Tanner staging scores, did not appear to be adversely affected in any of the treatment groups.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Noting that their results support and extend data from other studies, the authors said a realistic treatment goal for JIA should include therapy aimed at reducing inflammation to minimize disease-related disability, including growth impairment.

Commenting on the study, coauthor Daniel J. Lovell, MD, of the Children’s Hospital Medical Center in Cincinnati says, “this study adds to an ever growing list of positive outcomes for children with JIA treated with anti-[tumor-necrosis factor] TNF therapies. Anti-TNF biologic therapies have been shown to have a profound and comprehensive effect on both physiologic and psychosocial outcomes in children with polyarticular forms of JIA.”

Reference

1. Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:3259-3264.

Sue Pondrom is a medical journalist based in San Diego.

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Research Reviews Tagged With: A&R, Clinical research, etanercept, Juvenile idiopathic arthritis

You Might Also Like:
  • New Guidance for Rheumatologists who Treat JIA
  • Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • What Do JIA Patients Experience? A New Case Study from the ARP Practice Committee

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)